Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE: 300181)
Health Care · Pharmaceuticals · CN
CN¥14.15
-5.29% today · -29.0% 1Y
Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE: 300181) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.46B and employs 2,861 people.
Over the last twelve months the share price has lost 29.0%, trading between 12.30 and 20.16.
Tweenvest scores Zhejiang Jolly Pharmaceutical Co.,LTD across four factors: quality 78/100, value 81/100, growth 85/100, dividend 74/100. Its strongest factor is growth.
300181 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.46B
- Revenue (TTM)
- $451.49M
- P/E
- 15.11
- EPS
- 0.94
- Dividend yield
- 2.47%
- Beta (5Y)
- 0.13
- 52-week high
- CN¥20.16
- 52-week low
- CN¥12.30
- Avg volume (3M)
- —
- Shares outstanding
- 693.22M
- Employees
- 2,861
- Next earnings
- —
About Zhejiang Jolly Pharmaceutical Co.,LTD
Zhejiang Jolly Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, manufacturing, and global distribution of traditional Chinese medicinal products. The company's diverse portfolio includes the Wuling capsule, prescribed for conditions such as insomnia, amnesia, heart palpitations, general fatigue, weakness in the lower back and legs, and tinnitus. This capsule also addresses energy deficiency and a weak pulse often linked to an imbalance of the heart and kidneys, or neurasthenia. Additionally, they produce the Lingze tablet, which targets frequent or painful urination, weak or continuous urine flow, and lower back and knee soreness, especially when these symptoms are associated with benign prostatic hyperplasia, kidney insufficiency, or blood stasis. Another offering, the Bailing tablet, serves as an adjunctive treatment for coughs, asthma, back pain, and chronic bronchitis stemming from lung and kidney deficiencies. The firm also markets Linglianhua particles, used to manage symptoms including excessive sweating, sleep disturbances, irritability, heart flutters, vivid dreams, dizziness with tinnitus, lower back and leg weakness, dry stools, an unusual tongue appearance, and a feeble pulse, often seen in perimenopausal syndrome or heart and kidney disharmony. Beyond these traditional Chinese medicine formulations, Zhejiang Jolly Pharmaceutical provides a range of injectable pharmaceuticals, such as azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside. The company further supplies raw medicinal ingredients, including cordyceps cephalosporium, fermented cordyceps, and Wuling powders. Expanding its reach into healthcare services, Zhejiang Jolly Pharmaceutical Co., Ltd. invests in and participates with Deqing No.3 People's Hospital. Established in 2000 and based in Huzhou, China, the entity now known as Zhejiang Jolly Pharmaceutical Co., Ltd. adopted this name in 1998, evolving from its earlier designation, Zhejiang Jolly Pharmaceutical Health Products Co., LTD.
- ISIN
- CNE100001096
- Founded
- 1995
- Listed since
- Feb 22, 2011
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,239.69 | -1.25% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.54 | +0.48% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $149.86 | -1.76% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.10 | -1.73% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.32 | -1.70% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.88 | -0.68% |
Figures last refreshed Aug 18, 2026.